SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Job Trends
Bonus Episode: Q4 2024 Job Market Update
In this bonus episode, BioSpace’s vice president of marketing ⁠Chantal Dresner⁠ and careers editor ⁠Angela Gabriel⁠ take a look at Q4 job market performance and what we expect to see ahead.
January 21, 2025
 · 
1 min read
 · 
Angela Gabriel
Job Trends
BioSpace Showcases Life Sciences Hubs in 2025 Hotbed Maps
BioSpace has revealed its 2025 Hotbed Maps, showcasing nine regional hot spots for life sciences activity.
January 21, 2025
 · 
1 min read
 · 
Chantal Dresner
Graphic illustration with geometric shapes and textured brush strokes of iconic Cancer awareness and prevention ribbon. Art to be used for Cancer related themes such as support, encouragement, treatment and pre-screening.
Breast cancer
AstraZeneca, Daiichi Sankyo’s ADC Wins First Approval Despite Mixed Data
Datroway, formerly known as Dato-DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
January 21, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: Nasdaq headquarters in New York/iStock,
IPO
Sionna, Odyssey Join Growing 2025 IPO Class as Analysts Forecast ‘Muted’ Market
While some analysts expect the 2025 IPO market to be relatively cool in the near-term, others anticipate more bids than in 2024.
January 21, 2025
 · 
2 min read
 · 
Tristan Manalac
Art collage, hands and scales of justice. The concept of the law of the judge.
Legal
Sage Sues Partner Biogen After Unsolicited Takeover Offer
Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital Markets.
January 21, 2025
 · 
2 min read
 · 
Tristan Manalac
Cancer cells
Cancer
Reframing Multiple Myeloma: From Fatal to Chronic and Even Curable
Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, bispecifics and more contributing to multifaceted regimens unique to each patient’s needs.
January 21, 2025
 · 
8 min read
 · 
Kate Goodwin
Doubtful businessman stands in front of a crossroad with road split in three different ways as arrows shows opposed courses. Business challenge, choosing a correct pathway. Difficult decision concept
Lung cancer
After Tough 2024, AstraZeneca/Daiichi Sankyo Push Enters Key Period
Even before the FDA’s recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate could hit $5.9 billion in 2030. However, the asset faced a series of setbacks in 2024.
January 21, 2025
 · 
5 min read
 · 
Nick Paul Taylor
Medicine or pharmacy abstract geometric pattern. Corporate identity geometrical shape background or medicine presentation retro vector pattern with thermometer, stethoscope, lab flask and pills
Business
2025 Investment to Swing Toward I&I, Obesity, More: Experts
As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune diseases, a continued appetite for next-generation obesity drugs and an increased focus on neuromuscular, kidney and cardiovascular diseases.
January 21, 2025
 · 
7 min read
 · 
Heather McKenzie
Courtesy Getty Images
Opinion
New Treatments for Celiac Disease Gain Traction
There are currently no treatments available for celiac disease beyond a gluten-free diet. Several late-phase companies aim to change the paradigm and deliver hope and progress soon.
January 21, 2025
 · 
3 min read
 · 
Jia Jie Chen
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS